Personal Genome Diagnostics company logo

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

Founded Year



Acquired | Alive

Total Raised






About Personal Genome Diagnostics

Personal Genome Diagnostics (PGDx) develops tests for cancer at the genomic level, which incorporate sequencing algorithms to find alterations in genomes associated with cancer. The company is developing tests of both tissue samples and blood, the latter of which is known as "liquid biopsy." It is based in Baltimore, Maryland. On December 23rd, 2021, Personal Genome Diagnostics was acquired by LabCorp at a valuation between $450M and $575M.

Personal Genome Diagnostics Headquarter Location

2809 Boston Street Suite 503

Baltimore, Maryland, 21224,

United States


Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Research containing Personal Genome Diagnostics

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned Personal Genome Diagnostics in 2 CB Insights research briefs, most recently on Jan 3, 2022.

Expert Collections containing Personal Genome Diagnostics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Personal Genome Diagnostics is included in 7 Expert Collections, including Cancer.



3,710 items

Products/services that analyze tumor-derived biomarkers (ctDNA, CTCs, exosomes) in blood/urine/other non-invasive liquid specimens to detect cancer earlier, guide treatment, and monitor progress. *Data fields manually updated as new information becomes available.'


Medical Devices

11,943 items

Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.


Health Monitoring & Diagnostics

2,470 items

Companies developing or offering products that aid in the assessment, screening, diagnosis, or monitoring of a person's state of health/wellness. Excludes companies focused solely on fitness/sports performance



1,267 items

Companies involved in the capture, sequencing, and/or analysis of genomic, transcriptomic, proteomic, and/or metabolomic data


Biopharma Tech

260 items


Health IT

7,900 items

Personal Genome Diagnostics Patents

Personal Genome Diagnostics has filed 8 patents.

The 3 most popular patent topics include:

  • Molecular biology
  • Biotechnology
  • Genetics
patents chart

Application Date

Grant Date


Related Topics




Molecular biology, Genetics, DNA sequencing, DNA, Biotechnology


Application Date


Grant Date



Related Topics

Molecular biology, Genetics, DNA sequencing, DNA, Biotechnology



Latest Personal Genome Diagnostics News

Obesity associated with improved immunotherapy outcomes among certain patients with cancer

Jun 14, 2022

Disclosures: Chan reports grants from Personal Genome Diagnostics Inc., Pfizer and Varian; an advisory board role with Illumina; other support from Gritstone bio; stock and grants from NysnoBio outside the submitted work; and a patent for use of tumor mutational burden as a biomarker licensed to Personal Genome Diagnostics Inc. Please see the study for all other authors' relevant financial disclosures. ADD TOPIC TO EMAIL ALERTS Receive an email when new articles are posted on Please provide your email address to receive an email when new articles are posted on . Please try again later. If you continue to have this issue please contact . Back to Healio Obesity appeared associated with improved immunotherapy outcomes among patients with certain cancer types, according to a cohort study published in JAMA Network Open. “The benefits of obesity in patients treated with immune checkpoint blockade and the underlying mechanisms are being examined, but the scale and spectrum of benefit across cancer types is unknown,” Timothy A. Chan, MD, PhD, director of the Center for Immunotherapy and Precision Immuno-Oncology at Cleveland Clinic's Lerner Research Institute, and colleagues wrote. Data derived from Yoo SK, et al. JAMA Netw Open. 2022;doi:10.1001/jamanetworkopen.2022.0448. Background and methodology Chan and colleagues initiated the research to improve understanding of the obesity paradox : that obesity is both a risk factor for cancer but also may be associated with improved treatment outcomes. They evaluated pretreatment BMI of 1,840 patients (median age, 63.84 years; range, 55.66-71.16; 57.55% men) who received at least one dose of immune checkpoint blockade treatment between 2014 and 2019. Among the 16 cancer types represented in the cohort, the most common included non-small cell lung cancer (n = 639), renal cancer (n = 220) and melanoma (n = 209). Timothy A. Chan Chan and colleagues measured BMI within 30 days before treatment. They defined normal weight (BMI, 18.5 kg/m2 to 24.9 kg/m2), overweight (BMI, 25 kg/m2 to 29.9 kg/m2) and obesity (BMI, 30 kg/m2) according to WHO guidelines. Key findings Results of pancancer survival analyses showed patients with obesity had longer OS after immune checkpoint blockade treatment than patients with overweight (HR = 0.82; 95% CI, 0.7-0.96) or normal weight (HR = 0.67; 95% CI, 0.57-0.78). Researchers also observed longer OS following immune checkpoint blockade treatment among patients with overweight vs. normal weight (HR = 0.81; 95% CI, 0.71-0.93). In addition, patients with obesity had longer PFS than patients with overweight (HR = 0.89; 95% CI, 0.78-1.02) or normal weight (HR = 0.77; 95% CI, 0.68-0.87), and patients with overweight had longer PFS than patients with normal weight (HR = 0.86; 95% CI, 0.76-0.97). Obesity also appeared associated with higher radiographic response rates vs. normal weight or overweight. Further research Study limitations included small statistical power in subgroup analyses because of sample sizes and that the study did not address cancer type-specific confounding variables, including International Metastatic Renal Cell Carcinoma Database Consortium risk score. “Therefore, the results in some cancer types warrant further study with larger cohorts to address specific confounding variables in more detail,” the researchers wrote. “In addition, BMI is not a perfect assessment of obesity because it cannot distinguish muscle from body fat. Hence, body fat measurement methods such as dual-energy X-ray absorptiometry may have value in future studies.” Read more about

Personal Genome Diagnostics Web Traffic

Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Personal Genome Diagnostics Rank

  • When was Personal Genome Diagnostics founded?

    Personal Genome Diagnostics was founded in 2010.

  • Where is Personal Genome Diagnostics's headquarters?

    Personal Genome Diagnostics's headquarters is located at 2809 Boston Street, Baltimore.

  • What is Personal Genome Diagnostics's latest funding round?

    Personal Genome Diagnostics's latest funding round is Acquired.

  • How much did Personal Genome Diagnostics raise?

    Personal Genome Diagnostics raised a total of $260.27M.

  • Who are the investors of Personal Genome Diagnostics?

    Investors of Personal Genome Diagnostics include LabCorp, New Enterprise Associates, Windham Venture Partners, Innovatus Capital Partners, Rock Springs Capital and 17 more.

  • Who are Personal Genome Diagnostics's competitors?

    Competitors of Personal Genome Diagnostics include Natera and 3 more.

You May Also Like

Circuit Clinical Logo
Circuit Clinical

Circuit Clinical matches clinical trials to physicians' areas of interest, assists with patient recruitment, and studies visits while filing all regulatory requirements.

Tempus Logo

Tempus builds a library of molecular and clinical data as well as a corresponding operating system for data accessibility and use. The company enables physicians to deliver personalized cancer care for patients through its interactive analytical and machine learning platform. It provides genomic sequencing services and molecular and therapeutic data analysis to empower physicians to make real-time, data-driven decisions.

Antidote Logo

Antidote is a digital health company that uses precision recruitment to match the right patients with the right trials. Antidote strikes the right balance between technology and human touch to deliver patient engagement through the integration of data-driven technologies, digital expertise, deep domain experience, a diverse partner network, and personalized patient and site services.

Protean BioDiagnostics Logo
Protean BioDiagnostics

Protean BioDiagnostics is committed to creating and deploying laboratory diagnostic tools to support physicians.

GenomOncology Logo

GenomOncology develops technology to automate the analysis of sequenced genetic information. The company provides software and analytical tools that can interactively analyze and interpret sequenced genomic data. The technology is designed to detect and analyze gene mutations, a hallmark of the presence of cancer, within the sequenced genomes.

Caris Life Sciences Logo
Caris Life Sciences

Caris Life Sciences is an Irving, Texas-based provider of molecular science that assess DNA, RNA and proteins to reveal a molecular blueprint that allows physicians and cancer patients to make precise and personalized treatment decisions.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.